Lumeon Provides Real-Time Health System Orchestration to Cedars-Sinai Accelerator Powered by Techstars - Gilde Healthcare

Lumeon Provides Real-Time Health System Orchestration to Cedars-Sinai Accelerator Powered by Techstars

October 24, 2017

Leading Care Pathway Management Platform to Dynamically Personalize and Streamline Surgery Experience for Patients

BOSTONLumeon, the leader in Care Pathway Management, today announced its participation in the Cedars-Sinai Accelerator Powered by Techstars. Through the Accelerator, Lumeon is collaborating with Cedars-Sinai to identify digital care pathways that can be deployed in care settings throughout the U.S.

Leveraging its experience orchestrating pathways across multiple care specialties through Europe, Lumeon will enable U.S. providers to deliver care in an entirely new way, using intelligent automation. Its unique pathway approach fluidly connects care teams and automated processes, augmenting existing systems with real-time situational awareness.

Within the Accelerator, the company’s initial focus is on surgical pathways, with the aim of reducing cancelations, optimizing length of stay and lowering readmissions – problems that cost the U.S. healthcare industry billions of dollars each year. This approach will enable care teams to deliver a personalized and adaptive care plan for every patient.

“Today, no one has really solved the fundamental issue of care fragmentation, or found a way to deliver end-to-end personalized care at scale, without placing huge strain on resources,” said Lumeon CEO, Robbie Hughes. “The challenge is rarely the care decisions; it’s the difficulty operationalizing them into a longitudinal plan that reliably delivers the best possible care, every time, for every patient.”

“Hospitals around the country understand too well the costs associated with surgical pathways and the impact of same-day cancelations, complications and complex administrative processes,” said Bryan Croft, Senior Vice President Operations, at Cedars-Sinai. “We are excited to have Lumeon in the Accelerator to help explore solutions that can maximize value from our existing technology, and can scale for us across other departments, as well as across other hospitals throughout the U.S.”

“The outstanding surgeons in our system are singularly focused on providing the best possible outcomes for our patients,” said Bruce L. Gewertz, MD, Surgeon-in-Chief and Vice President for Interventional Services at Cedars-Sinai. “One of our key areas of focus is to understand the relationship between task, team, technology and environment. Lumeon has a solution that designs and operationalizes these relationships, adding real value to our patients and care teams.”

Matt Kozlov, Managing Director of the Cedars-Sinai Accelerator Powered by Techstars, added, “We are delighted that Lumeon is part of our 2017 accelerator cohort – we see real potential for the technology to expand across the U.S. hospital and ambulatory market, especially as it’s been built to adapt to each provider’s own care process model.”

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022